Cargando…
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis
The nitroimidazole DNDI-0690 is a clinical drug candidate for visceral leishmaniasis (VL) that also shows potent in vitro and in vivo activity against cutaneous leishmaniasis (CL). To support further development of this compound into a patient-friendly oral or topical formulation for the treatment o...
Autores principales: | Wijnant, Gert-Jan, Croft, Simon L., de la Flor, Raul, Alavijeh, Mo, Yardley, Vanessa, Braillard, Stéphanie, Mowbray, Charles, Van Bocxlaer, Katrien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709472/ https://www.ncbi.nlm.nih.gov/pubmed/31262757 http://dx.doi.org/10.1128/AAC.00829-19 |
Ejemplares similares
-
Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021) -
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019) -
Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis – challenges and opportunities
por: Van Bocxlaer, Katrien, et al.
Publicado: (2021) -
Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018) -
Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)